Drug intelligence / Profile preview

TB0001-EAP05

Development stage: Unknown
Lead developer: Tavo Biotherapeutics
Modality: Small Molecules
Administration: Ophthalmic

Overview

TB0001-EAP05 is an investigational topical ophthalmic solution of pregabalin, a gabapentinoid small molecule, being developed by Tavo Biotherapeutics for the treatment of primary open-angle glaucoma and ocular hypertension. The drug acts by binding to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels, a mechanism intended to lower intraocular pressure and potentially provide neuroprotective effects to the ocular tissues. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and efficacy in comparison to the prostaglandin analogue latanoprost.

Other names: pregabalin ophthalmic solution

Targets

CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on TB0001-EAP05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB0001-EAP05.

Explore the full profile